Fragil X Syndrome
-
Devon-Based CBD Developer Plans Reverse Stock Split
A Devon pharmaceutical company is working on cannabinoid therapies to treat genetic conditions. In the meantime, Zynerba Pharmaceuticals is planning a reverse stock split by…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
